https://siftingsignal.com/gisignals/What is worth knowing in GI this week. A SiftingSignal publication.https://siftingsignal.com/gisignals/2026-W35/https://siftingsignal.com/gisignals/2026-W35/Mon, 24 Aug 2026 19:12:09 +0000Issue 8, week of Aug 23, 2026: 41 papers analysed. Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study).; Hormonal contraception is not associated with recurrent flares in ulcerative colitis: a longitudinal time-dependent analysis.; Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies.; Coccidioidomycosis in patients with inflammatory bowel disease receiving advanced therapy: An observational study from an endemic tertiary center.; Intestinal flagellin drives multisystem inflammation through TLR5-IL-15-ARA axis.; Novel proteomic signatures of stricturing Crohn disease using a treatment-naive cohort.; Anti-Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross-Sectional Study.; GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.https://siftingsignal.com/gisignals/2026-W34/https://siftingsignal.com/gisignals/2026-W34/Thu, 20 Aug 2026 18:40:03 +0000Issue 7, week of Aug 16, 2026: 28 papers analysed. Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.; Prior adalimumab exposure alters infliximab pharmacokinetics and trough targets in pediatric Crohn's disease.; The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases.; Histological aging signatures for monitoring tissue-specific aging and disease.; Cancer Risk with Advanced Therapies in Patients with Inflammatory Bowel Diseases: An Administrative Claims-based Study.; Effect of high dose N-acetyl cysteine supplementation on markers of oxidative stress and insulin resistance in non-diabetic patients with metabolic dysfunction associated steatotic liver disease: a randomized controlled trial.; A First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis B.; Xenobiotic-Induced Liver Injury in the United States: A 25-Year Retrospective Analysis of National Poison Data System.https://siftingsignal.com/gisignals/2026-W33/https://siftingsignal.com/gisignals/2026-W33/Thu, 20 Aug 2026 21:35:47 +0000Issue 6, week of Aug 9, 2026: 52 papers analysed. Clinical appraisal of handheld intestinal ultrasound in inflammatory bowel disease: Where are we now?; Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study.; Multi-modal ensemble learning prediction of anti-TNF treatment response in pediatric patients with Crohn's disease using clinical, radiomic, and deep learning MR enterography features.; Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults.; Neutralising autoantibodies against IL-10 and HLA-DRB1*01:03 in paediatric patients with inflammatory bowel disease.; Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.; Prior adalimumab exposure alters infliximab pharmacokinetics and trough targets in pediatric Crohn's disease.; The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence.https://siftingsignal.com/gisignals/2026-W32/https://siftingsignal.com/gisignals/2026-W32/Thu, 06 Aug 2026 18:00:11 +0000Issue 5, week of Aug 2, 2026: 107 papers analysed. Trends in Substance Use Disorder Among Hospitalized Patients With Inflammatory Bowel Disease: An 11-Year Nationwide Study.; Fiber Intake in Inflammatory Bowel Disease: Impact of Disease Activity and Predictors of High Fiber Intake.; Suicide Attempts, Schizophrenia, and Depression Among Inflammatory Bowel Disease Patients: Data From a Large Database.; Artificial intelligence enhances screening efficiency for inflammatory bowel disease clinical trials: a prospective study.; Bowel urgency in inflammatory bowel disease: A concept analysis.; Transmural improvement may be an acceptable target in patients with Crohns disease.; Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials.; Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry.https://siftingsignal.com/gisignals/2026-W31/https://siftingsignal.com/gisignals/2026-W31/Thu, 30 Jul 2026 22:01:39 +0000Issue 4, week of Jul 26, 2026: 58 papers analysed. Is it always necessary to wait until day 5 for second line treatment in children with acute severe ulcerative colitis?; The hostile abdomen dilemma: the safety of primary anastomosis in the presence of an intraoperative abscess in Crohn disease.; The Impact of Fistulizing Disease, Treatment Modalities, and Clinical Activity on Health-Related Quality of Life in Crohn's Disease.; "The role of red cell distribution width in inflammatory bowel disease evaluation: a comprehensive systematic review and meta-analysis".; Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.; Impact of 5-aminosalicylic acid intolerance on progression to difficult-to-treat ulcerative colitis: a retrospective cohort study.; Fibrosis regression in chronic liver disease: the pathologist's view.; Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.https://siftingsignal.com/gisignals/2026-W30/https://siftingsignal.com/gisignals/2026-W30/Sat, 25 Jul 2026 22:16:33 +0000Issue 3, week of Jul 19, 2026: 28 papers analysed. Malignancy risk associated with upadacitinib in immune-mediated inflammatory diseases: a comparison with u.s. and global cancer registries.; Meta-analysis: safety and efficacy of ustekinumab in pediatric inflammatory bowel disease patients with anti-TNF failure.; Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study.; New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC.; Ustekinumab for fistulising perianal Crohn's disease: a randomised placebo-controlled trial from the GETAID.; The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.; Clonal diversity underpins distinct modes of recurrence in hepatocellular carcinoma: the PLANet cohort study.; Prior decompensation Identifies Patients at High Mortality Risk Despite Standard Therapy After Variceal Hemorrhage: An IPD Meta-analysis.https://siftingsignal.com/gisignals/2026-W29/https://siftingsignal.com/gisignals/2026-W29/Sat, 18 Jul 2026 20:04:34 +0000Issue 2, week of Jul 12, 2026: 17 papers analysed. Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.; Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.; IgA-Enriched Phenotype Predicts Liver-Related Events in MASLD.; A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: the CIRI model.; Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality.; Recompensation of decompensated cirrhosis in a spectrum of metabolic-dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors.; Meta-Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.; Comparison of Fully Covered Self-Expanding Metal Stents and Liquid Nitrogen Spray Cryotherapy for Malignant Esophageal Adenocarcinoma: A Retrospective Cohort Study.https://siftingsignal.com/gisignals/2026-W26/https://siftingsignal.com/gisignals/2026-W26/Thu, 09 Jul 2026 16:47:07 +0000Issue 1, week of Jun 24, 2026: 29 papers analysed. Prevalence of disability in inflammatory bowel disease: a systematic review and meta-analysis.; Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.; Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.; ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.; ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.; A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.; Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial.; Eosinophilic Esophagitis and Autoimmune Thyroid Disease: A Population-Based Matched Cohort Study.